Companies › Ascendis Pharma Growth Disorders
2 active drug programs in 2 registered trials: 2 Phase 2; Other; next expected readout Nov 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Lonapegsomatropin Growth hormone receptor agonist | GHR | Phase 2 | Achondroplasia | Nov 2027 |
| Navepegritide C-type natriuretic peptide (CNP) analog | NPR2 | Phase 2 | Achondroplasia | Nov 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06433557 | Navepegritide | Phase 2 | Achondroplasia | Other | Nov 2027 |
| NCT06433557 | Lonapegsomatropin | Phase 2 | Achondroplasia | Other | Nov 2027 |
BioMarin Pharmaceutical Novo Nordisk Changchun GeneScience Pharmaceutical Ascendis Pharma Endocrinology Division Ascendis Pharma
Ascendis Pharma Endocrinology Division Eirion Therapeutics Airway Therapeutics Inotrem Tego Science
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.